Dr. Westin focuses on developmental therapeutics and the use of biomarkers to predict response and recurrence in gynecologic malignancies. She currently serves as the Director of Early Drug Development and Phase I trials in the Department of Gynecologic Oncology and is a Co-Director of the Ovarian Cancer Moonshot. Dr. Westin is a member of the NRG Oncology – GOG Developmental Therapeutics, Phase I, and Early Phase Protocol Oversight committees. In addition to serving on the National Cancer Institute (NCI) Uterine Task Force and Gynecologic Cancer Steering Committee (GCSC), she serves as a co-chair of the GCSC Ovarian Cancer Task Force and the NCI Ovarian Cancer Clinical Trials Planning Meeting. As such, she is guiding development of future NCI trials designed to push the field forward and expand the role of precision medicine in ovarian cancer.
Dr. Westin is the co-PI for five major projects within her department’s SPOREs in Uterine Cancer and Ovarian Cancer. In addition, she is currently the PI or co-PI for greater than 30 novel treatment trials in gynecologic malignancies. Dr. Westin works on development of rational combinatorial therapies to treat advanced and recurrent gynecologic cancer, especially ovarian and endometrial cancer. Her trials are designed with strong translational endpoints to allow the bedside to inform future bench research. Further, she has an interest in exploring mechanisms of resistance to therapy which can be exploited in future clinical trial designs.
Education & Training
MD, University of Florida - College of Medicine. 2002
MPH, University of Texas Health Science Center at Houston, School of Public Health, 2008